- Home
- AXGN
AXGN
Axogen Inc.
as of 12-05-2025 4:00pm EST
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | ALACHUA |
| Market Cap: | 1.2B | IPO Year: | N/A |
| Target Price: | $33.67 | AVG Volume (30 days): | 904.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.21 - $34.24 | Next Earning Date: | 10-29-2025 |
| Revenue: | $214,709,000 | Revenue Growth: | 18.72% |
| Revenue Growth (this year): | 21.57% | Revenue Growth (next year): | 15.79% |
AI-Powered AXGN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Axogen Inc. (AXGN)
Director
Avg Cost/Share
$24.02
Shares
3,591
Total Value
$86,248.64
Owned After
100
SEC Form 4
Director
Avg Cost/Share
$24.01
Shares
19,227
Total Value
$461,640.27
Owned After
100
SEC Form 4
Director
Avg Cost/Share
$24.01
Shares
5,347
Total Value
$128,370.78
Owned After
100
SEC Form 4
Director
Avg Cost/Share
$24.05
Shares
11,431
Total Value
$274,892.69
Owned After
100
SEC Form 4
Director
Avg Cost/Share
$23.00
Shares
18,248
Total Value
$419,704.00
Owned After
100
SEC Form 4
Director
Avg Cost/Share
$20.58
Shares
40,235
Total Value
$827,013.23
Owned After
100
Director
Avg Cost/Share
$18.02
Shares
1,457
Total Value
$26,252.23
Owned After
100
SEC Form 4
Director
Avg Cost/Share
$18.00
Shares
736
Total Value
$13,248.74
Owned After
100
SEC Form 4
Director
Avg Cost/Share
$18.21
Shares
22,171
Total Value
$403,649.66
Owned After
100
Director
Avg Cost/Share
$18.01
Shares
10,020
Total Value
$180,424.39
Owned After
100
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Burke William P. Mr. | AXGN | Director | Nov 11, 2025 | Sell | $24.02 | 3,591 | $86,248.64 | 100 | |
| Burke William P. Mr. | AXGN | Director | Nov 10, 2025 | Sell | $24.01 | 19,227 | $461,640.27 | 100 | |
| Burke William P. Mr. | AXGN | Director | Nov 6, 2025 | Sell | $24.01 | 5,347 | $128,370.78 | 100 | |
| Burke William P. Mr. | AXGN | Director | Nov 5, 2025 | Sell | $24.05 | 11,431 | $274,892.69 | 100 | |
| Burke William P. Mr. | AXGN | Director | Oct 30, 2025 | Sell | $23.00 | 18,248 | $419,704.00 | 100 | |
| Burke William P. Mr. | AXGN | Director | Oct 29, 2025 | Sell | $20.58 | 40,235 | $827,013.23 | 100 | |
| Burke William P. Mr. | AXGN | Director | Oct 22, 2025 | Sell | $18.02 | 1,457 | $26,252.23 | 100 | |
| Burke William P. Mr. | AXGN | Director | Oct 6, 2025 | Sell | $18.00 | 736 | $13,248.74 | 100 | |
| Burke William P. Mr. | AXGN | Director | Oct 3, 2025 | Sell | $18.21 | 22,171 | $403,649.66 | 100 | |
| Burke William P. Mr. | AXGN | Director | Oct 2, 2025 | Sell | $18.01 | 10,020 | $180,424.39 | 100 |
Compare AXGN vs Leading Stocks
See how AXGN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AXGN Axogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.